AIkido Pharma Inc.
| NASDAQ: AIKI |
| Healthcare / Biotechnology / USA |
| 5.84 | +0.1800 | +3.18% | Vol 61.97K | 1Y Perf 460.40% |
| Jun 24th, 2022 15:59 DELAYED |
| BID | 5.83 | ASK | 5.86 | ||
| Open | 5.71 | Previous Close | 5.66 | ||
| Pre-Market | - | After-Market | 5.81 | ||
| - - | -0.03 -0.51% |
| Target Price | 2.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | -65.75 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 9.47 | Earnings Rating | — | |
| Market Cap | 203.93M | Earnings Date | 10th Aug 2022 | |
| Alpha | -0.03 | Standard Deviation | 0.30 | |
| Beta | 1.56 |
Today's Price Range 5.645.89 | 52W Range 4.3020.57 | 5 Year PE Ratio Range -0.80005.00 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 6.96% | ||
| 1 Month | 1 844.72% | ||
| 3 Months | 1 212.36% | ||
| 6 Months | 812.50% | ||
| 1 Year | 460.40% | ||
| 3 Years | 157.27% | ||
| 5 Years | 37.41% | ||
| 10 Years | -99.39% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -21.24 | |||
ROE last 12 Months | -10.08 | |||
ROA (5Y Avg) | -4.11 | |||
ROA last 12 Months | -8.99 | |||
ROC (5Y Avg) | -29.47 | |||
ROC last 12 Months | -9.78 | |||
Return on invested Capital Q | -6.84 | |||
Return on invested Capital Y | -1.77 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.90 | ||||
| 0.30 | ||||
| - | ||||
| 9.20 | ||||
| -3.30 | ||||
| -1.78 | ||||
| 0.30 | ||||
| 18.10 | ||||
| -13 697 000.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 82.30 | ||||
| 110.80 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -92 677.80 | ||||
| -92 677.80 | ||||
| -17 558.70 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -0.34 | -1.19 | -250.00 |
| Q03 2021 | -0.51 | 0.00 | 100.00 |
| Q02 2021 | - | -0.34 | - |
| Q01 2021 | - | -1.19 | - |
| Q02 2020 | - | -0.07 | - |
| Q01 2020 | - | -0.91 | - |
| Q03 2019 | - | -1.38 | - |
| Q02 2019 | - | -0.30 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 10th Aug 2022 |
| Estimated EPS Next Report | -0.68 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 61.97K |
| Shares Outstanding | 34.92K |
| Shares Float | 296.96K |
| Trades Count | 420 |
| Dollar Volume | 357.97K |
| Avg. Volume | 746.57K |
| Avg. Weekly Volume | 125.39K |
| Avg. Monthly Volume | 567.17K |
| Avg. Quarterly Volume | 1.55M |
AIkido Pharma Inc. (NASDAQ: AIKI) stock closed at 5.84 per share at the end of the most recent trading day (a 3.18% change compared to the prior day closing price) with a volume of 61.97K shares and market capitalization of 203.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5 people. AIkido Pharma Inc. CEO is Anthony Hayes.
The one-year performance of AIkido Pharma Inc. stock is 460.4%, while year-to-date (YTD) performance is 894.89%. AIKI stock has a five-year performance of 37.41%. Its 52-week range is between 4.3 and 20.57, which gives AIKI stock a 52-week price range ratio of 9.47%
AIkido Pharma Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 0.30, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 9.20, a PEG ratio of 2.32, a ROA of -8.99%, a ROC of -9.78% and a ROE of -10.08%. The company’s profit margin is -%, its EBITDA margin is -92 677.80%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from AIkido Pharma Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.68 for the next earnings report. AIkido Pharma Inc.’s next earnings report date is 10th Aug 2022.
The consensus rating of Wall Street analysts for AIkido Pharma Inc. is Strong Buy (1), with a target price of $2, which is -65.75% compared to the current price. The earnings rating for AIkido Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AIkido Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AIkido Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 84.03, ATR14 : 0.37, CCI20 : 63.57, Chaikin Money Flow : -0.05, MACD : 1.36, Money Flow Index : 72.69, ROC : 14.51, RSI : 86.35, STOCH (14,3) : 98.41, STOCH RSI : 0.11, UO : 62.24, Williams %R : -1.59), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AIkido Pharma Inc. in the last 12-months were:
AIkido Pharma Inc.
AIkido Pharma Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing a antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
CEO: Anthony Hayes
Telephone: +1 703 992-9325
Address: One Rockefeller Plaza, New York 10020, NY, US
Number of employees: 5
